echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Chemicals Industry > International Chemical > Issue 4, 2016 - Quick Facts

    Issue 4, 2016 - Quick Facts

    • Last Update: 2022-11-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The global active pharmaceutical ingredient market has a promising outlook

    According to the European Fine Chemicals Group (EFCG), the global active pharmaceutical ingredient (API) industry is picking up with a positive
    outlook for the coming years.
    Its main drivers include increased demand for high value-added products, the return of Western European and American companies that have shifted their operations to low-cost regions, and improved
    product quality and reliability in European companies.
    According to the EFCG, the global API market was worth $84 billion in 2014, and North America is the world's largest API market, with a market value of $12.
    5 billion in 2014, accounting for 29% of the global market; The European market reached $11.
    5 billion, followed by Latin America with $6.
    8 billion, or 16 percent
    .
    Global prescription drug sales are expected to grow rapidly before 2020, and the average annual compound growth rate will reach 4.
    8%
    during 2014~2020.

    Barclays: In 2016, global oil and gas company budgets will bottom out twice

    According to Barclays' annual oil and gas exploration and production expenditure outlook, a report conducted by Barclays after surveying 225 companies, global upstream oil and gas companies will cut spending by 15% in 2016 and 23%
    in 2015.
    This means that for the second time in Barclays' 31-year history of investigation, there has been a continuous reduction in spending, the first time occurred in
    1986~1987.
    Barclays believes that the continued decline in oil prices means that the spending budgets of oil and gas companies will fall further, because the budgets of these companies are generally based on the average price of Brent crude oil of $50/barrel and the average price of WTI crude oil of $45/barrel
    .
    The current oil price is about $30 per barrel
    .
    Barclays said that if oil prices can be maintained at $40 a barrel, global upstream oil and gas companies will cut spending by nearly 20%
    this year.

    U.
    S.
    ethanol exports will continue to grow

    Michael Dwyer, chief economist at the U.
    S.
    Grains Council (USGC), said U.
    S.
    ethanol exports will continue to grow
    for a long time to come.
    Based on USDA forecasts for U.
    S.
    corn prices through 2024 and OECD forecasts for global sugar prices, U.
    S.
    corn prices are expected to stabilize below $4/bushel, while sugar prices will remain above
    corn prices.
    In addition, the United States is wrestling market share
    from Brazilian ethanol producers.
    The Brazilian ethanol industry is facing economic recession and high interest rates, and it is difficult to compete with
    the United States due to multiple factors.
    On the contrary, the US ethanol industry is developing well
    .

     


    In 2015, the return on investment in pharmaceutical R&D reached a record low

    According to Deloitte's latest survey report of 12 large pharmaceutical companies around the world, including Amgen, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi and Takeda Pharmaceutical, although the US Food and Drug Administration (FDA) approved 45 new drugs in 2015, the number of approvals reached a record high in nearly two decades, but the return on R&D investment of large pharmaceutical companies hit a record low

    The average return on R&D investment by Big Pharma was only 4.
    2% in 2015, down from 10.
    1%
    in 2010.
    Deloitte attributes the record low return on R&D investment to higher development costs and lower revenue from
    drug sales.
    The average development cost per drug has risen 33 percent since 2010, reaching $1.
    58 billion in 2015, while projected peak sales revenue fell 50 percent to $416 million
    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.